Jean Philippe Metges

Author

Centre Hospitalier Régional Universitaire de Brest

Also Known As

J P Metges, J. -P. Metges, J. P. Metges, J.-P. Metges, Jean P. Metges, Jean Philippe Metges

Publications

446

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Régional Universitaire de Brest Centre Hospitalier de Lens Roche (France)Institut de Cancérologie de l'Ouest Universitat de Barcelona

About

Jean Philippe Metges is an author at Centre Hospitalier Régional Universitaire de Brest specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	163
2	Pathology	3	3	71
3	Health Sciences	1	1	13
4	Gastroenterology	1	1	13
5	Nephrology	1	1	13

Jean Philippe Metges

Publications

360

Citations

H-Index

Page 1

	Year	Citations
p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer Constantino Fondevila, Jean Philippe Metges, Josep Fuster, British Journal of Cancer	2004	182
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach M. Boisdron‐Celle, Olivier Capitain, Roger Faroux, Seminars in Oncology Preclinical Drug EvaluationPharmacologyToxicologyPharmacotherapyMetabolomics	2017	78
Positive VEGF Immunostaining Independently Predicts Poor Prognosis in Curatively Resected Gastric Cancer Patients: Results of a Study Assessing a Panel of Angiogenic Markers Óscar Vidal, Antonio Soriano-Izquierdo, Manuel Pera, Journal of Gastrointestinal Surgery Tumor BiologySurgical OncologyAngiogenesisGastrointestinal OncologyMedicine	2007	44
p53 protein accumulation in oesophageal squamous cell carcinomas and precancerous lesions. A Volant, J.‐B. Nousbaum, Marie-Agnès Giroux, Journal of Clinical Pathology	1995	15
A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification M. Boisdron‐Celle, Jean Philippe Metges, Olivier Capitain, Seminars in Oncology Drug SafetyOncologyPharmacologyPharmacotherapyMedicine	2017	14
Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500). Philip Agop Philip, Nathan Bahary, Amit Mahipal, Journal of Clinical Oncology First-line TherapyPathologyPharmacotherapyMetastatic Pancreatic CancerPancreatic Cancer	2022	14
Efficacy and safety of FOLFIRINOX in patients with metastatic pancreatic cancer. Jean Philippe Metges, Jean François Ramée, Jean‐Yves Douillard, Journal of Clinical Oncology Surgical OncologyCancer ManagementGastroenterologyPathologyPharmacotherapy	2014	13

Page 1